AVIR [NASD]
Atea Pharmaceuticals, Inc.
Index- P/E14.45 EPS (ttm)0.51 Insider Own10.52% Shs Outstand83.18M Perf Week2.80%
Market Cap591.53M Forward P/E- EPS next Y-2.56 Insider Trans0.14% Shs Float74.50M Perf Month25.68%
Income48.40M PEG- EPS next Q-0.52 Inst Own66.90% Short Float3.21% Perf Quarter18.01%
Sales285.40M P/S2.07 EPS this Y-268.60% Inst Trans2.78% Short Ratio2.95 Perf Half Y-4.30%
Book/sh8.17 P/B0.90 EPS next Y25.50% ROA6.00% Target Price7.50 Perf Year-63.45%
Cash/sh8.75 P/C0.84 EPS next 5Y- ROE7.50% 52W Range5.31 - 46.91 Perf YTD-17.90%
Dividend- P/FCF- EPS past 5Y- ROI17.00% 52W High-84.35% Beta-
Dividend %- Quick Ratio24.90 Sales past 5Y- Gross Margin- 52W Low38.23% ATR0.46
Employees64 Current Ratio24.90 Sales Q/Q295.20% Oper. Margin- RSI (14)59.69 Volatility4.99% 7.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-246.80% Profit Margin17.00% Rel Volume0.87 Prev Close7.53
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout0.00% Avg Volume811.67K Price7.34
Recom2.60 SMA2012.90% SMA5011.11% SMA200-46.84% Volume702,723 Change-2.52%
Jan-06-22Downgrade Morgan Stanley Equal-Weight → Underweight $14 → $7
Nov-18-21Downgrade SVB Leerink Outperform → Mkt Perform
Oct-20-21Downgrade JP Morgan Overweight → Neutral $61 → $16
Oct-05-21Downgrade Morgan Stanley Overweight → Equal-Weight $55
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
May-25-22 06:20AM  
May-11-22 10:28AM  
May-10-22 07:00PM  
06:30AM  
May-03-22 04:05PM  
Apr-01-22 05:13AM  
Mar-30-22 12:48PM  
Mar-28-22 07:00AM  
Mar-21-22 10:04AM  
Feb-28-22 10:00PM  
07:19PM  
06:40PM  
04:05PM  
Feb-22-22 07:00AM  
Feb-16-22 02:19PM  
01:57PM  
Feb-14-22 09:31AM  
Feb-11-22 07:00AM  
Feb-10-22 07:00AM  
Feb-09-22 07:00AM  
Feb-02-22 05:38PM  
01:38PM  
07:00AM  
Jan-28-22 05:05AM  
Jan-07-22 07:00AM  
Jan-03-22 07:00AM  
Dec-28-21 08:27AM  
05:00AM  
Dec-17-21 07:00AM  
Dec-14-21 04:30PM  
Dec-12-21 12:24PM  
Dec-10-21 06:38PM  
Dec-01-21 08:47AM  
Nov-25-21 07:35AM  
Nov-22-21 07:00AM  
Nov-17-21 10:32AM  
08:13AM  
08:09AM  
Nov-16-21 05:25PM  
04:58PM  
04:30PM  
Nov-12-21 05:00AM  
Nov-11-21 04:01PM  
Nov-04-21 07:53AM  
06:50AM  
Nov-01-21 03:21PM  
Oct-31-21 06:19AM  
Oct-30-21 08:39AM  
Oct-29-21 06:05AM  
Oct-26-21 07:00AM  
06:45AM  
Oct-25-21 02:39PM  
Oct-24-21 10:00AM  
Oct-22-21 07:42PM  
Oct-20-21 09:04PM  
11:10AM  
10:09AM  
Oct-19-21 04:05PM  
12:55PM  
12:11PM  
12:02PM  
11:56AM  
10:08AM  
09:51AM  
07:00AM  
04:28AM  
Oct-17-21 06:04AM  
Oct-15-21 04:30PM  
Oct-12-21 04:00PM  
Oct-11-21 08:27AM  
Oct-08-21 08:30AM  
Oct-07-21 07:00AM  
Oct-05-21 10:00AM  
Oct-04-21 10:00AM  
Oct-03-21 04:00PM  
Oct-01-21 12:21PM  
11:50AM  
Sep-29-21 07:00AM  
Sep-20-21 01:18PM  
Sep-18-21 12:11PM  
Sep-10-21 12:19PM  
Sep-07-21 07:00AM  
Aug-24-21 07:00AM  
Aug-13-21 01:37AM  
12:00AM  
Aug-12-21 04:05PM  
Aug-05-21 07:00AM  
06:39AM  
Aug-04-21 09:39AM  
Jul-12-21 07:00AM  
Jun-30-21 11:11AM  
07:00AM  
Jun-16-21 09:26AM  
07:00AM  
Jun-15-21 07:00AM  
May-26-21 07:00AM  
May-25-21 12:41AM  
May-20-21 07:00AM  
May-15-21 03:26AM  
May-13-21 04:05PM  
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murphy Polly A.DirectorDec 20Buy8.5712,000102,79623,295Dec 21 09:41 PM